Taken together, these findings support ANXA1’s central role in the angiogenesis process and, thus, targeting ANXA1 represents a promising therapeutic strategy in vascularization inhibition and, consequently, in cancer progression inhibition [23]. Here, ANXA1 is linked to cancer.